Product Description
4-pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[1-methyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]-6-oxo-, methyl ester: A peptide drug intermediate for synthesizing immunosuppressants and antibiotics.
AI Product Description
*The following content is generated by AI and is for reference only.
The chemical entity known as 1,6-dihydro-5-hydroxy-2-[1-methyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]-4-pyrimidinecarboxylic acid is a sophisticated synthetic intermediate primarily utilized in the realm of medicinal chemistry and pharmaceutical research. This complex molecule features a pyrimidine core substituted with a carboxylic acid group, a hydroxyl moiety, and a protected amino acid side chain. The presence of the phenylmethoxycarbonyl (Cbz or Z) protecting group on the ethylamine segment indicates its strategic role in multi-step organic synthesis, where temporary protection of amine functionalities is required to ensure chemoselectivity during subsequent reactions.
While specific commercial Catalog CAS numbers for this exact stereochemical variant may vary depending on the supplier and enantiomeric purity, it serves as a critical building block for the development of novel bioactive compounds, particularly those targeting nucleic acid interactions or enzymatic inhibition. The pyrimidine scaffold is a ubiquitous motif in biologically active molecules, including antiviral agents, anticancer drugs, and kinase inhibitors. By incorporating this specific derivative, researchers can explore structure-activity relationships (SAR) to optimize drug candidates for improved potency, selectivity, and metabolic stability.
In laboratory settings, this compound is typically handled under anhydrous conditions to prevent premature hydrolysis of the ester or carbamate linkages. It finds application in peptide coupling reactions, heterocyclic synthesis, and the preparation of advanced pharmacophores. The Cbz group offers robust stability under basic conditions but can be cleanly removed via catalytic hydrogenation or strong acidic treatment when the final product requires a free amine. Consequently, this substance acts as a versatile precursor for constructing complex heterocyclic systems essential for modern drug discovery programs. Its structural complexity allows for fine-tuning molecular properties, making it an invaluable asset for academic institutions and pharmaceutical companies engaged in the early stages of lead optimization. Although not a standalone therapeutic agent itself, its contribution to the synthesis pipeline is significant, bridging the gap between simple starting materials and potent clinical candidates.